MAP2K7 and familial pancreatic carcinoma: But it was the limitation of this study that we haven’t conducted experiments to investigate whether the expression of CASP4/NLRP1 influenced the sensitivity of pancreatic cancer to these drugs., such as comparing tumor growth by using MEK or AKT inhibitors in vivo with animals.